PEPTONIC MEDICAL AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.06 SEK | -.--% |
|
-.--% | +3.45% |
| Apr. 17 | Peptonic Medical Plans SEK61 Million Shares, Warrants Issue | MT |
| Apr. 15 | Peptonic Medical Secures US Patent for Vaginal Yeast Infections Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Peptonic Medical AB is a Sweden-based company active in the field of biotechnology. The Company develops estrogen-free pharmaceuticals for treatment of vaginal atrophy. The Company's main drug candidate is Vagitocin, an oxytocin-based pharmaceutical preparation for the treatment of vaginal atrophy and other menopause-related symptoms. The patented treatment is based on local, vaginal application of oxytocin to rejuvenate the vaginal mucosa. Vagitocin is to enter phase III clinical trials in Europe and the United States.
Calendar
2024-05-06
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +3.45% | 8.4M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PMED Stock
- News PEPTONIC medical AB
- Women’s Health Companies Peptonic, Pharmiva to Merge
